Mechanistically, integrin β3 is induced by increased levels of TGFβ1 in acquired TKI-resistant lung cancer, which indicates the TGFβ1/integrin β3 axis as a potential target for combination therapy in EGFR-mutant lung cancer to overcome acquired resistance to EGFR TKIs (215). This evidence concerns the gene EGFR and lung cancer.